| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.883880 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107170714 |
|---|
| 006 | m o d f |
|---|
| 007 | cr |n||||||||| |
|---|
| 008 | 200123e19770916oncd||| o f00| 0|eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aRG23-130/1977E-PDF |
|---|
| 245 | 00|aStrategy and activity discussion : |bretail price disclosure of prescription drugs / |cBureau of Consumer Affairs. |
|---|
| 264 | 1|a[Ottawa] : |b[Consumer and Corporate Affairs Canada], |cSeptember 16, 1977. |
|---|
| 300 | |a1 online resource (1 volume (various pagings)) : |bcharts |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aDigitized edition from print [produced by Innovation, Science and Economic Development Canada]. |
|---|
| 520 | |a"Adequate price disclosure, a major ingredient found in all other consumer purchasing decisions, is practically non-existent in the dispensing of prescription drugs and appears to severely restrict consumer choice and free market competition. In May, 1977, Mediaspec Inc. submitted "A Report on Prescription Drug Price Disclosure" commissioned by the Bureau of Consumer Affairs exploring this issue, and Consumer Services Branch, in collaboration with Consumer Research Branch, was asked to evaluate the findings and conceive a complete strategy for Bureau action. Based on our evaluation and investigation, and with the concurrence of Consumer Research Branch, this paper proposes what we believe to be the most desirable course of action for the Bureau"--Introduction. |
|---|
| 650 | 0|aDrugs|xPrices|zCanada. |
|---|
| 650 | 6|aMédicaments|xPrix|zCanada. |
|---|
| 710 | 1 |aCanada.|bBureau of Consumer Affairs, |eissuing body. |
|---|
| 856 | 40|qPDF|s790 KB|uhttps://publications.gc.ca/collections/collection_2021/isde-ised/RG23-130-1977-eng.pdf |
|---|